Cancer Treatment: Types, Goals, and How They Work

Treatment Intent: Curative vs. Palliative

The most important cancer treatment question is not “which drug?” — it is “what is the goal?” Every treatment decision flows from the answer.

Treatment timing terms:

• Neoadjuvant: Given before surgery — to shrink the tumor, enable organ-sparing resection, or assess the tumor’s biological response to therapy. Pathologic complete response (pCR) after neoadjuvant treatment is a favorable prognostic marker in breast and rectal cancer.
• Adjuvant: Given after surgery — to eliminate micrometastatic disease that imaging cannot detect and reduce recurrence risk.
• Concurrent chemoradiation (CRT): Chemotherapy given simultaneously with radiation; the chemo acts as a radiosensitizer. Standard in head/neck, cervical, rectal, esophageal cancers.

Understanding which category your treatment falls into is one of the most important cancer diagnosis questions you can ask your oncologist before starting.

Surgery

Surgery is the oldest cancer treatment and the cornerstone of curative therapy for most solid tumors. The goal is to remove the tumor and an adequate margin of surrounding normal tissue.

Types of Cancer Surgery

• Curative resection (R0): Complete removal with clear margins — no cancer cells at the cut edge. R1 (microscopic positive margin) and R2 (macroscopic residual) are associated with higher recurrence risk.
• Debulking (cytoreductive surgery): Removes as much tumor as possible when complete removal isn’t feasible — used in ovarian cancer and peritoneal carcinomatosis. Maximizes response to subsequent chemotherapy.
• Sentinel lymph node biopsy: Removes only the first draining lymph node to check for spread — avoiding full axillary dissection in node-negative breast cancer and melanoma.
• Prophylactic surgery: Risk-reducing mastectomy in BRCA1/2 carriers reduces breast cancer risk by ~90%; colectomy prevents colorectal cancer in familial adenomatous polyposis.
• Reconstructive surgery: Breast reconstruction after mastectomy; flap surgery after head/neck resection.

Radiation Therapy

Radiation uses high-energy particles to damage cancer cell DNA. It can be delivered externally (beams aimed at the body) or internally (sources placed inside the tumor).

External Beam Radiation

• IMRT (Intensity-Modulated Radiation Therapy): Modulates radiation intensity within each beam for precise dose delivery to the tumor while sparing adjacent normal tissues. Standard for head and neck, prostate, and cervical cancers.
• SBRT/SABR (Stereotactic Body Radiation Therapy): Very high dose in just 3–5 fractions delivered to small, well-defined targets. Achieves 90–95% local control for small lung tumors — equivalent to surgery in selected cases. Also used for liver, spine, kidney, and prostate.
• Proton beam: Uses protons with Bragg peak physics — dose at a specific depth with minimal exit radiation. Most beneficial in pediatric cancers and skull base tumors. Equivalent survival to IMRT for most adult cancers in randomized data.
• Hypofractionation (FAST-Forward trial, Lancet 2020): 5 fractions of breast radiation over 1 week — non-inferior to 15 fractions over 3 weeks, with dramatically improved patient convenience.

Brachytherapy

Radioactive sources placed inside or adjacent to the tumor — delivers very high local dose with rapid falloff to surrounding normal tissue. HDR brachytherapy (Iridium-192) is used in cervical, endometrial, breast, and prostate cancers. LDR permanent seeds (Iodine-125) are a standard option for low-risk prostate cancer.

Chemotherapy

Chemotherapy uses drugs to kill rapidly dividing cells. Cancer cells divide faster than most normal cells, making them selectively vulnerable — but chemotherapy also affects normal rapidly-dividing cells (hair follicles, GI mucosa, bone marrow), which explains its characteristic side effects.

Key Regimens

Response to chemotherapy is assessed by CT scan every 2–3 cycles using RECIST 1.1 criteria: Complete Response (CR), Partial Response (≥30% reduction), Stable Disease, or Progressive Disease (≥20% increase or new lesions).

Targeted Therapy

Targeted therapy blocks specific molecular drivers of cancer growth — proteins or pathways that the cancer depends on. Unlike chemotherapy, targeted therapy requires a matching biomarker. Without the matching driver, the drug doesn’t work. This is why molecular testing of the biopsy is inseparable from treatment planning — and why cancer staging and biomarker profiling should always be complete before treatment starts.

Immunotherapy

Cancer immunotherapy redirects the immune system — which cancer has learned to evade — to recognize and destroy tumor cells. It has produced some of the most durable treatment responses in oncology history.

Checkpoint Inhibitors

T cells carry checkpoint proteins (PD-1, CTLA-4) that act as “off switches” preventing autoimmune damage. Cancer cells exploit these checkpoints to hide from immune attack. Checkpoint inhibitors block these switches, re-activating T cells against the tumor.

• PD-1 inhibitors: Pembrolizumab (Keytruda), nivolumab (Opdivo) — FDA-approved across 20+ cancer types including lung, melanoma, head/neck, gastric, cervical, endometrial, MSI-H solid tumors
• CTLA-4 inhibitor: Ipilimumab (Yervoy) — combined with nivolumab; CHECKMATE-067 showed 52% 5-year OS in metastatic melanoma with the combination vs. 26% with ipilimumab alone
• Response rates: 20–40% single agent; 40–60%+ in MSI-H tumors; responders often achieve durable, years-long remissions

Biomarkers predicting response: PD-L1 expression (TPS ≥1% or ≥50%), MSI-H/dMMR status (strongest predictor), and tumor mutation burden (TMB-high ≥10 mut/Mb). Understanding your cancer grade and biomarker profile determines whether immunotherapy is appropriate for your cancer.

Immune-related adverse events (irAEs): T cells activated against tumors can also attack normal tissues — causing colitis, pneumonitis, thyroiditis, hepatitis, or adrenal insufficiency. Grade 3–4 irAEs are managed with high-dose corticosteroids and treatment hold.

CAR-T Cell Therapy

CAR-T (chimeric antigen receptor T cell) therapy extracts a patient’s own T cells, engineers them to express a tumor-targeting receptor, expands them to hundreds of millions, and reinfuses them.

FDA-approved CAR-T products include:

• Axicabtagene ciloleucel (Yescarta): 3rd-line+ DLBCL — ZUMA-1 trial: 39% complete response rate; approximately 30–35% long-term remission at 5-year follow-up
• Tisagenlecleucel (Kymriah): B-cell ALL in children/young adults; 2nd-line+ DLBCL
• Idecabtagene vicleucel, ciltacabtagene autoleucel: Relapsed/refractory multiple myeloma
• CAR-T is now also approved in the 2nd-line setting for DLBCL (ZUMA-7 and TRANSFORM trials showed superiority over standard salvage chemotherapy)

Major toxicities: CRS (cytokine release syndrome) — fever, hypotension, hypoxia from massive immune activation, managed with tocilizumab. ICANS (immune effector cell-associated neurotoxicity) — managed with dexamethasone.

Cancer Vaccines

• HPV vaccine (Gardasil 9): Prevents HPV 16, 18, and 7 other strains — prevents cervical, head/neck, anal, vulvar, vaginal, and penile cancers associated with HPV. One of the most effective cancer prevention tools available.
• Personalized mRNA neoantigen vaccines: KEYNOTE-942 (Phase II, ASCO 2023): mRNA-4157 (Moderna) + pembrolizumab in resected Stage III/IV melanoma significantly reduced recurrence or death vs. pembrolizumab alone (HR 0.56). Phase III trials ongoing.

Hormone Therapy (Endocrine Therapy)

For hormone-driven cancers, blocking hormone production or signaling can halt tumor growth.

Breast Cancer

• Tamoxifen: Blocks estrogen receptor in breast tissue. EBCTCG meta-analyses: tamoxifen reduces recurrence by ~50% and mortality by ~30% over 5–10 years in ER+ breast cancer.
• Aromatase inhibitors (AIs): Anastrozole, letrozole, exemestane — block peripheral estrogen synthesis. Superior to tamoxifen in postmenopausal women; standard first-line endocrine therapy.
• CDK4/6 inhibitors + endocrine therapy: Palbociclib, ribociclib, abemaciclib significantly extend progression-free survival in metastatic HR+/HER2- breast cancer (MONALEESA, MONARCH, PALOMA trials). Abemaciclib also approved adjuvantly for high-risk early-stage disease.
• Elacestrant (EMERALD trial, FDA 2023): First oral SERD — for ESR1-mutated metastatic HR+ breast cancer after prior endocrine therapy.

Prostate Cancer

• ADT (androgen deprivation therapy): LHRH agonists (leuprolide, goserelin) or antagonists (degarelix, relugolix) — suppress testosterone to castrate levels (<50 ng/dL). Cornerstone of locally advanced and metastatic prostate cancer treatment.
• Abiraterone (Zytiga): CYP17A1 inhibitor; combined with prednisone. LATITUDE and STAMPEDE trials: OS benefit when added to ADT in metastatic hormone-sensitive prostate cancer.
• Enzalutamide, apalutamide, darolutamide: Next-generation AR antagonists for hormone-sensitive and castration-resistant settings.

Stem Cell Transplant

Autologous SCT: Patient’s own stem cells are collected, stored, then reinfused after high-dose chemotherapy to rescue the bone marrow. Standard consolidation in multiple myeloma; used in relapsed Hodgkin lymphoma and NHL.

Allogeneic SCT: Donor cells provide a graft-vs.-leukemia (GVL) immune effect in addition to bone marrow rescue. Used in AML, ALL, MDS, and CML. Main toxicity: GVHD (graft-vs.-host disease), where donor immune cells attack normal host tissues.

The Multidisciplinary Team

Most cancer patients receive treatment from a team rather than a single physician. Medical oncologist, surgical oncologist, radiation oncologist, pathologist, and radiologist should all review complex cases — ideally at a formal tumor board. Palliative care, nutrition, and social work are integral components of comprehensive cancer care.

Before starting treatment, ask about tumor board review — see our cancer diagnosis questions guide. If you have any doubt about your treatment plan, a cancer second opinion can confirm or refine the approach. For decisions by cancer type and stage, see our cancer treatment options guide.